Role of a Clinical Pharmacist on Drotrecogin Alfa (activated) Outcomes in a Large Community Teaching Hospital

2004 ◽  
Vol 6 (3) ◽  
pp. 55-68 ◽  
Author(s):  
Srividya Kotapati
Keyword(s):  
Teaching Hospital ◽  
Clinical Pharmacist ◽  
Drotrecogin Alfa ◽  
Large Community ◽  
Drotrecogin Alfa Activated ◽  
Community Teaching

scholarly journals Use of Drotrecogin Alfa (Activated) in Bariatric Surgery Patients with Severe Sepsis Syndrome: Experience in an Urban Community Teaching Hospital

2004 ◽  
Vol 14 (1) ◽  
pp. 107-115 ◽  
Author(s):  
Richard H. Savel ◽  
Ravi C. Pulipati ◽  
Connie Mangone-Cholewczynski ◽  
Richard S. Lazzaro ◽  
Jerzy M. Macura ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Severe Sepsis ◽  
Teaching Hospital ◽  
Drotrecogin Alfa ◽  
Urban Community ◽  
Sepsis Syndrome ◽  
Drotrecogin Alfa Activated ◽  
Community Teaching

M1432: Qualitative Evolution of Colonoscopy - An Analysis Over 10 Years of Continuous Practice At a Large Community, Teaching Hospital

2010 ◽  
Vol 71 (5) ◽  
pp. AB219-AB220
Author(s):  
Arjun Vaid ◽  
Mariann Padron ◽  
Brenda Jimenez ◽  
Roger D. Mitty
Keyword(s):  
Teaching Hospital ◽  
Large Community ◽  
Qualitative Evolution ◽  
Community Teaching

scholarly journals Protected code blue: using in situ simulation to develop a protected code blue and modify staff training protocol—experience in a large community teaching hospital during the COVID-19 pandemic

2021 ◽  
Vol 10 (1) ◽  
pp. e001097
Author(s):  
Fady A Youssef ◽  
Monique Patel ◽  
Hyunsoon Park ◽  
Jay V Patel ◽  
James Leo ◽  
...  
Keyword(s):  
Teaching Hospital ◽  
Healthcare Workers ◽  
Care Delivery ◽  
Control Measures ◽  
High Exposure ◽  
In Situ Simulation ◽  
Team Members ◽  
Large Community ◽  
Code Blue ◽  
Community Teaching

The surge in clinical demand, shortage in personal protective equipment and high-exposure risk for healthcare workers during the COVID-19 pandemic has challenged hospital common practices and forced a reassessment of care delivery models. Code blue teams are highly specialised units that partake in life-saving situations that can jeopardise the safety of team members. There is a paucity of guidance in regards to proper infection control measures to protect the responders.This study describes a methodical approach to assessing vulnerabilities to transmission of SARS-CoV-2 within existing code blue practices, modalities to limit the number of code blue team responders and modifications to the protocol at a large community teaching hospital. The effort undertaken faced challenges due to the nature of the pandemic and the increased demand on healthcare workers. Quality improvement methods facilitated our protocol design and implementation. To this date, there has been no identified COVID-19 disease in any protected code blue (PCB) team members. We recommend that similar practices be considered and adopted widely and practised periodically.

Evaluation of a Pharmacy-Managed Pharmacokinetic Dosing Program

2014 ◽  
Vol 28 (6) ◽  
pp. 529-534 ◽  
Author(s):  
Lyndsi K. Meyenburg ◽  
Andrew J. Crannage ◽  
Julie A. Murphy ◽  
Matthew J. Korobey
Keyword(s):  
Creatinine Clearance ◽  
Teaching Hospital ◽  
Financial Outcomes ◽  
Large Community ◽  
Additional Support ◽  
The Impact ◽  
Community Teaching

Purpose: The objective of this study was to determine the impact of a pharmacy-managed pharmacokinetic dosing program on appropriate dosing of famotidine, enoxaparin, and ketorolac. Methods: A large community teaching hospital implemented a pharmacy-managed pharmacokinetic dosing program for famotidine, enoxaparin, and ketorolac. Subjects were included if they received famotidine and had a creatinine clearance (CrCl) of <50 mL/min; received therapeutic enoxaparin and had a CrCl of <30 mL/min; or received ketorolac and had a CrCl <30 mL/min, age > 65 years or weight <50 kg. Results: One hundred and forty-six patients were included in the preimplementation group (famotidine [n = 50], enoxaparin [n = 46], and ketorolac [n = 50]) and 143 patients were included in the postimplementation group (famotidine [n = 50], enoxaparin [n = 43], and ketorolac [n = 50]). In all, 66% of patients were dosed appropriately in the preimplementation group (famotidine 28%, enoxaparin 85%, and ketorolac 86%) compared to 94% in the postimplementation group (famotidine 92%, enoxaparin 95%, and ketorolac 94%), P < .001. Conclusion: Implementation of a pharmacy-managed pharmacokinetic dosing program significantly improved appropriate dosing of famotidine, enoxaparin, and ketorolac. These findings could justify expansion of pharmacist autonomy through institution–approved, pharmacy-managed programs for other medications to improve appropriate dosing. Analyses specifically evaluating patient-oriented or financial outcomes may provide additional support for expansion.

Sign in / Sign up

Export Citation Format

Share Document